



Express Mail No. EV 654 850 850 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Fleischer and Reimer

Confirmation No.: 9935

Serial No.: 09/701,450

Art Unit: 1615

Filed: November 27, 2000

Examiner: Gollamudi S. Kishore

For: PREPARATIONS FOR THE APPLICATION OF
ANTI-INFLAMMATORY, ESPECIALLY
ANTISEPTIC AGENTS AND/OR AGENTS
PROMOTING THE HEALING OF WOUNDS TO
THE LOWER RESPIRATORY TRACT

Attorney Docket No: 11390-005-999

AMENDMENT FEE TRANSMITTAL SHEET

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: October 26, 2005

Samuel B. Abrams 30,605
Samuel B. Abrams (Reg. No.)

By: William J. Thomann 40,203
William J. Thomann (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017-6702
(212) 901-9028



Express Mail No.: EV 654 850 850 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Fleischer and Reimer

Confirmation No.: 9935

Serial No.: 09/701,450

Group Art Unit: 1615

Filed: November 27, 2000

Examiner: Gollamudi S. Kishore

For: PREPARATIONS FOR THE APPLICATION OF
ANTI-INFLAMMATORY, ESPECIALLY
ANTISEPTIC AGENTS AND/OR AGENTS
PROMOTING THE HEALING OF WOUNDS
TO THE LOWER RESPIRATORY TRACT

Attorney Docket No.: 11390-005-999

REPLY UNDER 37 C.F.R. § 1.111 WITH AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the outstanding Office Action, mailed December 22, 2004, please enter the following amendments and consider the remarks made below in connection with the above-identified application. Submitted herewith is (a) a Petition to Revive an Unintentionally Abandoned Application under 37 C.F.R. §1.137(b); (b) an Amendment Fee Transmittal Sheet; (c) a Second Supplemental Information Disclosure Statement with a List of References Cited; and (d) a copy of each of References B16 and C23-C28.

Remarks begin on page 2 of this paper.